Pimecrolimus
Elidel is an anti-inflammatory medicine for use on the skin. It does not contain steroids.
The medicine works on the skin cells that cause inflammation, characteristic redness of the skin
and itching.
Treatment of patients from 3 months of age with mild or moderate atopic dermatitis,
when topical corticosteroids are not recommended or are not possible.
These may include:
Follow your doctor's instructions carefully.
Read the leaflet before using the medicine.
Before starting treatment with Elidel, discuss it with your doctor.
Elidel should not be used if the patient has a weakened immune system (immunity is
impaired).
Elidel is not intended for use in infants under 3 months of age.
Elidel is intended only for use in atopic dermatitis. It should not be used for other skin diseases.
In patients with severe atopic dermatitis, during treatment with Elidel, there may be an increased risk of bacterial skin infections (eczema herpeticum).
Elidel should not be used on areas with malignant or premalignant skin changes.
Before starting treatment with Elidel, inform your doctor about any malignant tumors (cancer) or impaired (weakened) immune system.
Elidel is intended only for use on the skin. It should not be used on mucous membranes,
including the nasal mucosa, eyes, and oral mucosa. In case of accidental contact with the eyes or mucous membranes, the medicine should be removed immediately and rinsed with water.
Be careful not to swallow the medicine or accidentally get it into the mouth, e.g., when applying it to the hands.
The medicine should not be used on skin surfaces infected with viruses, such as herpes simplex (cold sore) or chickenpox.
If the skin is infected, the doctor may prescribe a suitable medicine to treat the infection. Only after the infection has been treated can Elidel treatment be started. If an infection occurs during Elidel treatment, inform your doctor. In this case, the doctor will advise stopping Elidel until the infection is treated.
Elidel may increase the risk of severe skin infection with herpes virus (eczema herpeticum). If painful blisters appear on the body, inform your doctor immediately. Elidel treatment should be stopped until the infection is treated.
Elidel may cause reactions at the application site, such as a feeling of heat or burning.
These reactions are usually mild and resolve quickly. Inform your doctor if you experience severe reactions while using Elidel.
When using Elidel, do not cover the treated skin with a bandage or dressing, but you can wear normal clothes.
During treatment with Elidel, avoid excessive exposure to sunlight, sunlamps, and tanning beds. If you are going to be outside, protect your skin with appropriate clothing and use sunscreen with a high sun protection factor (SPF) and limit your time in the sun as much as possible.
It is not recommended to use Elidel in case of erythroderma (redness of almost the entire body) or a skin disease called Netherton's syndrome. Before starting treatment with Elidel, inform your doctor if you have these diseases.
If you experience swelling of the lymph nodes while using Elidel, consult your doctor immediately.
In patients with severe infection and/or damaged skin, systemic concentrations may be higher.
Consult your doctor, even if the above warnings refer to situations that have occurred in the past.
Tell your doctor about all medicines you are taking or have recently taken, as well as any medicines you plan to use.
Pimecrolimus is not recommended for use at the vaccination site during local reactions.
In case of widespread atopic dermatitis, treatment with Elidel may be interrupted before administration of any vaccines. Your doctor will inform you if this is necessary.
Elidel should not be used at the same time as treatment with radiation (e.g., UVB, UVA, PUVA) or immunosuppressive medicines (e.g., azathioprine or cyclosporine).
During treatment with Elidel, avoid excessive exposure of the skin to sunlight.
The occurrence of interactions with other medicines is unlikely.
In rare cases, shortly after consuming alcohol, a sudden feeling of heat, rash, burning sensation, itching, or swelling may occur.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, consult your doctor or pharmacist before using this medicine.
Do not use Elidel during pregnancy.
It is not known whether the active substance in Elidel passes into breast milk after application to the skin. Do not use Elidel on the breast skin during breastfeeding.
Elidel has no influence or negligible influence on the ability to drive and use machines.
Cetyl alcohol and stearyl alcohol may cause local skin reactions (e.g., contact dermatitis).
Elidel contains 50 mg of propylene glycol (E 1520) per 1 g of cream. Propylene glycol (E 1520) may cause skin irritation. Due to the presence of propylene glycol, the medicine should not be used on open wounds or large areas of damaged or broken skin (e.g., burned skin) without consulting a doctor or pharmacist. Benzyl alcohol may cause allergic reactions and mild local irritation.
This medicine should always be used as directed by your doctor. If you are unsure, consult your doctor or pharmacist.
Elidel is applied to the affected areas of the skin, including the head, face, and neck, as well as skin folds.
The medicine is usually applied as described below.
Elidel should be applied twice a day, e.g., once in the morning and once in the evening. During treatment with Elidel, moisturizers can be used. When using moisturizers, apply them directly after using Elidel.
Do not bathe, shower, or swim immediately after applying Elidel, as this may wash off the cream.
The medicine can be used for a short or long period, with breaks, to prevent relapse of the disease.
Stop using Elidel as soon as the symptoms of atopic eczema have resolved.
Continue using Elidel for as long as your doctor recommends.
Stop treatment and consult your doctor if there is no improvement or if the symptoms of atopic eczema worsen after 6 weeks.
In long-term treatment of atopic eczema, Elidel should be reapplied as soon as symptoms (redness and itching) appear. This helps prevent relapse of the disease. If symptoms return, consult your doctor. The doctor will consider whether to restart treatment.
Due to the lack of sufficient data, Elidel should not be used in children under 3 months of age.
The dosage and method of administration in infants (from 3 to 23 months), children (from 2 to 11 years), and adolescents (from 12 to 17 years) are the same as for adult patients.
Atopic dermatitis (atopic eczema) rarely occurs in people over 65 years of age.
It has not been assessed whether the response to Elidel in elderly patients differs from that in younger patients.
If you feel that the effect of the medicine is too strong or too weak, consult your doctor.
If you have applied too much cream to the skin, wipe it off.
If you miss a dose of Elidel, apply it as soon as possible and then continue with the usual recommended dosage.
If you have any further doubts about using this medicine, consult your doctor.
If you accidentally swallow Elidel, inform your doctor immediately.
Like all medicines, Elidel can cause side effects, although not everybody gets them.
The most common side effects associated with Elidel are reactions (e.g., discomfort) at the application site. These reactions are usually mild and/or moderate, occur at the beginning of treatment, and are short-lived.
Very common(occurring in more than 1 in 10 patients)
Feeling of heat or burning at the application site.
Common(occurring in less than 1 in 10 patients)
Irritation, itching, and redness at the application site. Skin infections (folliculitis).
Uncommon(occurring in less than 1 in 100 patients)
Skin infections such as furuncles, eczema herpeticum (bacterial skin infection), herpes simplex, shingles, herpes simplex infection (eczema herpeticum), molluscum contagiosum (viral skin infection), skin warts (warts). Skin reactions at the application site, such as rash, pain, paresthesia (tingling, numbness), scaling, dryness, swelling, and worsening of atopic dermatitis symptoms.
Rare(occurring in less than 1 in 1000 patients)
Alcohol intolerance, feeling of heat, rash, burning sensation, itching, or swelling shortly after drinking alcohol. Allergic reactions, which can cause angioedema (swelling, usually of the face, limbs, and joints), skin rash, or urticaria. Skin color changes (a part of the skin may become darker or lighter than the surrounding skin).
Very rare(occurring in less than 1 in 10,000 patients)
Severe allergic reactions (anaphylactic reactions) with symptoms such as sudden shortness of breath and pain or tightness in the chest, swelling of the eyelids, face, and lips.
If you experience any of these symptoms, stop using the medicine and consult your doctor immediately.
There have been reports of malignant tumors, including lymphoma and skin cancer, in patients using Elidel.
Patients using Elidel have experienced lymph node enlargement, but a link to Elidel treatment has not been established.
If you experience any side effects, including any side effects not listed in the leaflet, tell your doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety, Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych, Al. Jerozolimskie 181C, 02-222 Warszawa, tel.: + 48 22 49 21 301, fax: + 48 22 49 21 309;
website: https://smz.ezdrowie.gov.pl.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep the medicine out of the sight and reach of children.
Do not store above 25°C. Do not freeze.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
After opening the tube, the medicine can be used for 12 months.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
A white, homogeneous, odorless cream that does not stain and is easy to spread.
A tube in a cardboard box.
1 tube of 15 g
For more detailed information, consult the marketing authorization holder or parallel importer.
Viatris Healthcare Limited
Damastown Industrial Park
Mulhuddart, Dublin 15, Dublin, Ireland
MEDA Manufacturing
Avenue J.F. Kennedy
33700 Mérignac, France
InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw
InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Marketing authorization number in Latvia, the country of export:02–0184
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.